JAMA internal medicine
The most recent articles from:
JAMA Intern Med
-
JAMA internal medicine · Sep 2014
Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.
One in 6 American men will be diagnosed as having prostate cancer during their lifetime. Although there are no data to support the use of primary androgen-deprivation therapy (ADT) for early-stage prostate cancer, primary ADT has been widely used for localized prostate cancer, especially among older patients. ⋯ Primary ADT is not associated with improved long-term overall or disease-specific survival for men with localized prostate cancer. Primary ADT should be used only to palliate symptoms of disease or prevent imminent symptoms associated with disease progression.